Learn more

DEUTSCHES INST ERNAEHRUNGSFORS

Overview
  • Total Patents
    30
About

DEUTSCHES INST ERNAEHRUNGSFORS has a total of 30 patent applications. Its first patent ever was published in 1997. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Germany. Its main competitors in its focus markets pharmaceuticals, measurement and foods and drinks are ENVIRONMENTAL MEDICINE AND OPERATIONAL MEDICINE RES INSTITUTE ACADEMY OF MILITARY MEDICAL SCIENCES, OPEXA THERAPEUTICS INC and FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA.

Patent filings per year

Chart showing DEUTSCHES INST ERNAEHRUNGSFORSs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Meyerhof Wolfgang 19
#2 Kuhn Christina 13
#3 Bufe Bernd 9
#4 Brockhoff Anne 8
#5 Behrens Maik 8
#6 Krautwurst Dietmar 7
#7 Appendino Giovanni 6
#8 Hofmann Thomas 5
#9 Raguse Jan-Dirk 3
#10 Bedner Peter 3

Latest patents

Publication Filing date Title
WO2010099983A1 Methods for isolating agonists and antagonists of taste receptors
EP2058404A1 Zfp69, Znf642 and Znf643 as markers for obesity-associated diabetes
EP1983342A1 Antogonists of bitter taste receptors and uses thereof
EP1978105A1 TBC1D1 as a marker in the response to dietary fat and obesity
EP1975611A1 Agonists of bitter taste receptors and uses thereof
EP1975612A1 Agonists of bitter taste receptors and uses thereof
WO2006053771A2 Agonists of bitter taste receptors and uses thereof
KR20070053659A Agonists of a bitter taste receptor and uses thereof
WO2005043158A1 Recombined cell system for deorphanizing g protein-coupled receptors
DE10350054A1 Recombinant cell system for deorphating G protein-coupled receptors
DE10255852A1 Process for the expression modification of polypeptides in recombinant expression systems
DE19849652A1 Pharmaceutical composition active against intestinal carcinoma
DE19751483A1 Modified potato starch, used in food, paint and textile industries
DE19749096A1 Non-steroidal anti-inflammatory drug or COX-II inhibitor with few side effects